The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia
Open accessAbstract
Blast crisis chronic myelogenous leukemia (CML-BC) and Philadelphia chromosome-positive (Ph1-positive) acute lymphocytic leukemia (ALL) are 2 fatal BCR/ABL-driven leukemias against which Abl kinase inhibitors fail to induce a long-term response. We recently reported that functional loss of protein phosphatase 2A (PP2A) activity is important for CML blastic transformation. We assessed the therapeutic potential of the PP2A activator FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride), an immunomodulator in Phase III trials for patients with multiple sclerosis or undergoing organ transplantation, in CML-BC and Ph1 ALL patient cells and in in vitro and in vivo models of these BCR/ABL+ leukemias. Our data indicate that FTY720 induces apoptosis and impairs clonogenicity of imatinib/dasatinib-sensitive and -resistant p210/p190(BCR/ABL) myeloid and lymphoid cell lines and CML-BC(CD34+) and Ph1 ALL(CD34+/CD19+) progenitors but not of normal CD34+ and CD34+/CD19+ bone marrow cells. Furthermore, pharmacologic doses of FTY720 remarkably suppress in vivo p210/p190(BCR/ABL)-driven [including p210/p190(BCR/ABL)(T315I)] leukemogenesis without exerting any toxicity. Altogether, these results highlight the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly support the introduction of the PP2A activator FTY720 in the treatment of CML-BC and Ph1 ALL patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationJanssens, V., & Goris, J. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3530417 · Cited by 1,902
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationDaley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200176200 · Cited by 1,504
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
Self-citationThe development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
Self-citationBiologically active sphingolipids in cancer pathogenesis and treatment
Ogretmen, B., & Hannun, Y. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1411 · Cited by 1,213
Wang, E., Norred, W. P., Bacon, C. W., Riley, R. T., & Merrill, A. H. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98712-0 · Cited by 1,113
O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
Self-citationModulation of Akt kinase activity by binding to Hsp90
Sato, S., Fujita, N., & Tsuruo, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170276797 · Cited by 967
Iron-Catalyzed Cross-Coupling Reactions
Fürstner, A., Leitner, A., Méndez, M., & Krause, H. (2002) · Journal of the American Chemical Society · doi:10.1021/ja027190t · Cited by 823
Melo, J. (1996) · Blood · doi:10.1182/blood.v88.7.2375.bloodjournal8872375 · Cited by 723
Ceramide activates heterotrimeric protein phosphatase 2A
Dobrowsky, R. T., Kamibayashi, C., Mumby, M. C., & Hannun, Y. A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82288-8 · Cited by 665
Discovery and evaluation of inhibitors of human sphingosine kinase.
French, K. J., Schrecengost, R. S., Lee, B. D., Zhuang, Y., Smith, S. N., Eberly, J. L., Yun, J. K., & Smith, C. D. (2003) · PubMed · Cited by 599
The biology of CML blast crisis
Calabretta, B., & Perrotti, D. (2004) · Blood · doi:10.1182/blood-2003-12-4111 · Cited by 592
Self-citationDissection of the protein kinase cascade by which nerve growth factor activates MAP kinases
Gómez, N., & Cohen, P. (1991) · Nature · doi:10.1038/353170a0 · Cited by 569
Ottmann, O. G. (2002) · Blood · doi:10.1182/blood-2001-12-0181 · Cited by 555
Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
Bedi, A., Zehnbauer, B., Barber, J., Sharkis, S., & Jones, R. (1994) · Blood · doi:10.1182/blood.v83.8.2038.2038 · Cited by 508
Li, S., Ilaria, R. L., Million, R. P., Daley, G. Q., & Van Etten, R. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1399 · Cited by 501
The Myeloid Leukemia-associated Protein SET Is a Potent Inhibitor of Protein Phosphatase 2A
Li, M., Makkinje, A., & Damuni, Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.19.11059 · Cited by 479
Brinkmann, V., Cyster, J. G., & Hla, T. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00476.x · Cited by 478
Neviani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B. W., Liu, S., Mao, H., Chang, J. S., Galietta, A., Uttam, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.015 · Cited by 476
Self-citationCross, N. C. P., Feng, L., Chase, A., Bungey, J., Hughes, T., & Goldman, J. M. (1993) · Blood · doi:10.1182/blood.v82.6.1929.1929 · Cited by 365
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia
Castor, A., Nilsson, L., Åstrand-Grundström, I., Buitenhuis, M., Ramirez, C., Anderson, K., Strömbeck, B., Garwicz, S., Békássy, A. N., Schmiegelow, K., et al. (2005) · Nature Medicine · doi:10.1038/nm1253 · Cited by 334
Windh, R. T., Lee, M.-J., Hla, T., An, S., Barr, A. J., & Manning, D. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27351 · Cited by 333
Protein phosphatase 2A: the Trojan Horse of cellular signaling
Sontag, E. (2001) · Cellular Signalling · doi:10.1016/s0898-6568(00)00123-6 · Cited by 330
Chiba, K. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.002 · Cited by 321
BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2
Perrotti, D., Cesi, V., Trotta, R., Guerzoni, C., Santilli, G., Campbell, K., Iervolino, A., Condorelli, F., Gambacorti-Passerini, C., Caligiuri, M. A., et al. (2002) · Nature Genetics · doi:10.1038/ng791 · Cited by 313
Self-citationCohen, M. H., Johnson, J. R., & Pazdur, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0722 · Cited by 282
Westbrook, C., Hooberman, A., Spino, C., Dodge, R., Larson, R., Davey, F., Wurster- Hill, D., Sobol, R., Schiffer, C., & Bloomfield, C. (1992) · Blood · doi:10.1182/blood.v80.12.2983.2983 · Cited by 274
Self-citationFirst Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients
Budde, K., Schmouder, R. L., Brunkhorst, R., Nashan, B., Lu[Combining Diaeresis]cker, P. W., Mayer, T., Choudhury, S., Skerjanec, A., Kraus, G., & Neumayer, H. H. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1341073 · Cited by 270
Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720
Zemann, B., Kinzel, B., Müller, M., Reuschel, R., Mechtcheriakova, D., Urtz, N., Bornancin, F., Baumruker, T., & Billich, A. (2006) · Blood · doi:10.1182/blood-2005-07-2628 · Cited by 264
Cross, N. C. P., Melo, J. V., Feng, L., & Goldman, J. M. (1994) · PubMed · Cited by 257
Cobaleda, C., Gutiérrez-Cianca, N., Pérez-Losada, J., Flores, T., Garcı́a-Sanz, R., González, M., & Sánchez-Garcı́a, I. (2000) · Blood · doi:10.1182/blood.v95.3.1007.003k35_1007_1013 · Cited by 249
Control of protein phosphatase 2A by simian virus 40 small-t antigen.
Yang, S. I., Lickteig, R. L., Estes, R., Rundell, K., Walter, G., & Mumby, M. C. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.4.1988 · Cited by 246
BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice
Voncken, J., Kaartinen, V, Pattengale, P., Germeraad, W., Groffen, J., & Heisterkamp, N. (1995) · Blood · doi:10.1182/blood.v86.12.4603.bloodjournal86124603 · Cited by 216
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias
Shah, N. P., & Sawyers, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206942 · Cited by 216
Roy, L., Guilhot, J., Krahnke, T., Guerci-Bresler, A., Druker, B. J., Larson, R. A., O'Brien, S., So, C., Massimini, G., & Guilhot, F. (2006) · Blood · doi:10.1182/blood-2006-02-001495 · Cited by 216
Self-citationCortez, D., Reuther, G., & Pendergast, A. M. (1997) · Oncogene · doi:10.1038/sj.onc.1201400 · Cited by 216
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation
Notari, M., Neviani, P., Santhanam, R., Blaser, B. W., Chang, J.-S., Galietta, A., Willis, A. E., Roy, D. C., Caligiuri, M. A., Marcucci, G., et al. (2006) · Blood · doi:10.1182/blood-2005-09-3732 · Cited by 202
Self-citationThe biology and therapy of adult acute lymphoblastic leukemia
Faderl, S., Jeha, S., & Kantarjian, H. M. (2003) · Cancer · doi:10.1002/cncr.11664 · Cited by 193
Azuma, H., Takahara, S., Ichimaru, N., Wang, J. D., Itoh, Y., Otsuki, Y., Morimoto, J., Fukui, R., Hoshiga, M., Ishihara, T., et al. (2002) · PubMed · Cited by 193
Transformation of Human and Murine Fibroblasts without Viral Oncoproteins
Boehm, J. S., Hession, M. T., Bulmer, S. E., & Hahn, W. C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.15.6464-6474.2005 · Cited by 171
Biology of chronic myelogenous leukemia—signaling pathways of initiation and transformation
Melo, J. V., & Deininger, M. W. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.03.008 · Cited by 166
Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question
HOOF, C. V., & Goris, J. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(03)00029-6 · Cited by 155
Iron-Catalyzed Cross-Coupling Reactions. A Scalable Synthesis of the Immunosuppressive Agent FTY720
Seidel, G., Laurich, D., & Fürstner, A. (2004) · The Journal of Organic Chemistry · doi:10.1021/jo049885d · Cited by 153
A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells
Matsuoka, Y., Nagahara, Y., Ikekita, M., & Shinomiya, T. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705182 · Cited by 152
Kim, Y., Sachs, T. E., Asavaroengchai, W., Bronson, R. T., & Sykes, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16950 · Cited by 135
Tölle, M., Levkau, B., Keul, P., Brinkmann, V., Giebing, G., Schönfelder, G., Schäfers, M. A., Lipinski, K. V. W., Jankowski, J., Jankowski, V., et al. (2005) · Circulation Research · doi:10.1161/01.res.0000164321.91452.00 · Cited by 122
Induction of Apoptosis in Human Bladder Cancer Cells In Vitro and In Vivo Caused by FTY720 Treatment
Azuma, H., Takahara, S., Horie, S., Muto, S., Otsuki, Y., & Katsuoka, Y. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000064938.32318.91 · Cited by 109
FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance
Yasui, H., Hideshima, T., Raje, N. S., Roccaro, A. M., Shiraishi, N., Kumar, S. K., Hamasaki, M., Ishitsuka, K., Tai, Y., Podar, K., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0850 · Cited by 104
Alvarado-Kristensson, M., & Andersson, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409718200 · Cited by 101
FTY720: A Promising Agent for Treatment of Metastatic Hepatocellular Carcinoma
Lee, T. K., Man, K., Ho, J. W., Wang, X. H., Poon, R. T. P., Xu, Y. Y., Ng, K. T., Chu, A. C., Sun, C. K.-W., Ng, I. O., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0447 · Cited by 98
Multiple‐Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects
Kovarik, J. M., Schmouder, R., Barilla, D., Rivière, G., Wang, Y., & Hunt, T. L. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004264165 · Cited by 95
Uckun, F. M., Dıbırdık, İ., Smith, R. J., Tuel-ahlgren, L., Chandan-Langlie, M., Schieven, G. L., Waddick, K. G., Hanson, M., & Ledbetter, J. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.9.3589 · Cited by 86
Ho, J. W., Man, K., Sun, C. K.-W., Lee, T. K., Poon, R. T. P., & Fan, S. T. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0021 · Cited by 86
Moon, E., & Lerner, A. (2003) · Blood · doi:10.1182/blood-2002-10-3208 · Cited by 79
FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation
Lee, T. K., Man, K., Ho, J. W., Sun, C. K.-W., Ng, K. T., Wang, X. H., Wong, Y. C., Ng, I. O., Xu, R., & Fan, S. T. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh250 · Cited by 79
FTY720, a Novel Immunosuppressive Agent, Induces Apoptosis in Human Glioma Cells
Sonoda, Y., Yamamoto, D., Sakurai, S., Hasegawa, M., Aizu-Yokota, E., Momoi, T., & Kasahara, T. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4352 · Cited by 70
Chronic myeloid leukaemia: stem cell derived but progenitor cell driven
Marley, S. B., & Gordon, M. Y. (2005) · Clinical Science · doi:10.1042/cs20040336 · Cited by 61
Involvement of Protein Phosphatase 2A in the Interleukin-3-Stimulated Jak2-Stat5 Signaling Pathway
Yokoyama, N., Reich, N., & Miller, W. (2001) · Journal of Interferon and Cytokine Research · doi:10.1089/107999001750277844 · Cited by 54
Yopp, A. C., Ochando, J., Mao, M., Ledgerwood, L. G., Ding, Y., & Bromberg, J. S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.2913 · Cited by 49
Developing therapeutics for the treatment of multiple sclerosis
Virley, D. J. (2005) · NeuroRx · doi:10.1602/neurorx.2.4.638 · Cited by 49
Saydam, G., Aydın, H. H., Şahin, F., Selvi, N., Öktem, G., Terzıoğlu, E., Büyükkeçeci, F., & Omay, S. B. (2003) · Leukemia Research · doi:10.1016/s0145-2126(02)00347-8 · Cited by 46
FTY720: a new immunosuppressive agent with novel mechanism(s) of action
Kahan, B. D. (1998) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)00593-4 · Cited by 39
Jendiroba, D. B., Klostergaard, J., Keyhani, A., Pagliaro, L. C., & Freireich, E. J. (2002) · Leukemia Research · doi:10.1016/s0145-2126(01)00129-1 · Cited by 30
Kahan, B. D. (2004) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.01.092 · Cited by 26
Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells
Butler, J., Lana, D., Round, O., & LaMontagne, K. R. (2004) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2003.11.003 · Cited by 22
Comparison of Imatinib, AMN107 and Dasatinib in an Accelerated Cell-Based Mutagenesis Screen.
Deininger, M. W., Bradeen, H. A., Jia, T., O’Hare, T., Willis, S. G., Lee, F., & Druker, B. J. (2005) · Blood · doi:10.1182/blood.v106.11.691.691 · Cited by 9
Self-citation
Research works printed but not linked: 14
- Savage, 1997, Br. J. Haematol., 96, 111, 10.1046/j.1365-2141.1997.d01-1982.x · doi:10.1046/j.1365-2141.1997.d01-1982.x
- Cohen, 2005, Clin. Cancer Res., 11, 12, 10.1158/1078-0432.12.11.1 · doi:10.1158/1078-0432.12.11.1
- Deininger, 2005, Blood (ASH Annual Meeting Abstracts)., 106, 691
- Brinkmann, 2004, Yonsei Med. J., 45, 991, 10.3349/ymj.2004.45.6.991 · doi:10.3349/ymj.2004.45.6.991
- Dumont, 2005, IDrugs., 8, 236
- Skerjanec, 2005, J. Clin. Pharmacol., 45, 1268, 10.1177/0091270005279799 · doi:10.1177/0091270005279799
- Janssens, 2001, Biochem. J., 353, 417, 10.1042/bj3530417 · DOI · Paper page
- French, 2003, Cancer Res., 63, 5962
- Azuma, 2002, Cancer Res., 62, 1410
- Xin, 2004, Br. J. Pharmacol., 143, 581, 10.1038/sj.bjp.0705980 · doi:10.1038/sj.bjp.0705980
- Suzuki, 2004, Proc. Natl. Acad. Sci. U. S. A., 101, 14788, 10.1073/pnas.0406536101 · DOI
- 10.1172/JCI200316950 · doi:10.1172/jci200316950
- Cross, 1994, Leukemia., 8, 186
- Hattori, 1995, Leuk. Res., 19, 389, 10.1016/0145-2126(95)00004-8 · doi:10.1016/0145-2126(95)00004-8
Cited by
Wymann, M. P., & Schneiter, R. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2335 · Cited by 1,291
Sphingosine 1-phosphate and cancer
Pyne, N. J., & Pyne, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2875 · Cited by 852
Molecular biology of bcr-abl1–positive chronic myeloid leukemia
Quintás-Cardama, A., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-03-144790 · Cited by 745
Self-citationProtein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond
Kunkel, G. T., Maceyka, M., Milstien, S., & Spiegel, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4099 · Cited by 434
Metadata
- Authors
- Neviani, P., Santhanam, R., Oaks, J. J., Eiring, A. M., Notari, M., Blaser, B. W., Liu, S., Trotta, R., Muthusamy, N., Gambacorti-Passerini, C., Druker, B. J., Cortes, J., Marcucci, G., Chen, C.-S., Verrills, N. M., Roy, D. C., Caligiuri, M. A., Bloomfield, C. D., Byrd, J. C., & Perrotti, D.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-09-04
- Volume
- 117
- Issue
- 9
- Pages
- 2408-2421
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1975748957
- Cited by
- 335
- References
- 72
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.